← Back to Search

Vaccine Education for Rheumatic Diseases

N/A

Recruiting

Led By Rosalind Ramsey-Goldman, MD, DrPH

Research Sponsored by Northwestern University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

Study Summary

This trial tests whether training community leaders can help more Black adults with rheumatic conditions get the COVID-19 vaccine and boosters.

Who is the study for?

This trial is for Black individuals aged 18-85 with rheumatic diseases who want to help their community understand COVID-19 vaccines better. They must speak English, identify as Black/African American/African descent, and have a social network. Members of this network should be adults not fully vaccinated against COVID.Check my eligibility

What is being tested?

The study tests two types of training given to Popular Opinion Leaders (POLs) in the Black community on the benefits of COVID-19 vaccines and boosters. The goal is to see if these trainings can increase vaccine uptake and reduce hesitancy within their networks.See study design

What are the potential side effects?

Since this trial focuses on educational interventions rather than medical treatments, there are no direct side effects from medications or vaccines being studied here.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Receipt of >1 COVID-19 vaccine or booster dose

Secondary outcome measures

Change in COVID-19 vaccine hesitancy

Structure and composition of the Popular Opinion Leader outreach networks.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: COVID-19 vaccine and booster training with extra undisclosed componentExperimental Treatment1 Intervention

Group training involving COVID-19 vaccine and booster information, including background, development, and myths. Contains extra training component that is undisclosed until the end of the study so as not to introduce bias.

Group II: COVID-19 vaccine and booster trainingActive Control1 Intervention

Group training involving COVID-19 vaccine and booster information, including background, development, and myths.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor

1,589 Previous Clinical Trials

917,066 Total Patients Enrolled

Brigham and Women's HospitalOTHER

1,616 Previous Clinical Trials

11,470,888 Total Patients Enrolled

Boston Children's HospitalOTHER

761 Previous Clinical Trials

5,579,870 Total Patients Enrolled

Media Library

COVID-19 vaccine and booster training with extra undisclosed component Clinical Trial Eligibility Overview. Trial Name: NCT05822219 — N/A

Coronavirus Vaccines Research Study Groups: COVID-19 vaccine and booster training with extra undisclosed component, COVID-19 vaccine and booster training

Coronavirus Vaccines Clinical Trial 2023: COVID-19 vaccine and booster training with extra undisclosed component Highlights & Side Effects. Trial Name: NCT05822219 — N/A

COVID-19 vaccine and booster training with extra undisclosed component 2023 Treatment Timeline for Medical Study. Trial Name: NCT05822219 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants still welcome to partake in this experiment?

"Clinicaltrials.gov indicates that this clinical trial, which was initially made available on May 1st 2023 and last modified on April 7th 2023, is not actively accepting enrollees at the moment. However, there are 1051 other trials currently seeking participants as of now."

Answered by AI

Who has the opportunity to be part of this experiment?

"This research is seeking 60 individuals aged between 18 and 85 who are suffering from lupus. To be eligible, potential participants must fulfil the following criteria: a minimum age of eighteen years old, any gender identity, proficiency in English or Haitian Creole/Spanish (depending on their primary language), not having been fully vaccinated against Covid-19."

Answered by AI

Does this research trial include elderly participants aged 70 or older?

"To participate in this trial, patients must be between 18 and 85 years old. As an alternative, there are 160 trials available for minors and 906 studies open to seniors over the age of 65."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases

Rosalind Ramsey-Goldman 2024. "Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05822219.

All > Covid 19